×

Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

Curis, Inc. Logo

LEXINGTON, Mass., April 23, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on Tuesday, April 30, 2013, before the market opens. The Company's management will also hold a conference call on the same day at 9:00 A.M. Eastern time to provide an overview of its proprietary research and development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge® (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the three-month period ended March 31, 2013. Daniel Passeri, Chief Executive Officer of Curis, will host the call.

To access the live conference call, please dial (877) 868-1829 from the U.S. or (253) 237-1135 from other locations, shortly before 9:00 a.m. EDT. The conference ID number is 35916940. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. A replay will be available approximately two hours after the completion of the call through 12:00 a.m. EDT, Tuesday, May 7, 2013. To access the replay, please dial (855) 859-2056 from the United States or (404) 537-3406 from other locations and reference conference ID number 35916940.

About Curis, Inc.

Curis is an oncology-focused company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/HER2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.

CONTACT: Michael P. Gray Chief Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com

Source:Curis, Inc.